{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:44:00Z","timestamp":1788385440561,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The activation of EphA2 receptor by its natural ligand EphrinA1 causes blood brain barrier dysfunction, and inactivation of EphA2 reduces BBB damage in ischemic stroke. Thus, EphA2 targeted antagonists may serve as neuroprotective agents. We engineered four mutants of EphrinA1, EM1, EM2, EM3 and EM4, respectively. The computational analysis showed that these four mutants were capable of interacting with EphA2. Their potential neuroprotective effects were examined in mouse focal ischemia\/reperfusion (I\/R) model. EM2 exhibited strong neuroprotective effects, including reduced brain infarct volume, neuronal apoptosis, cerebral edema, and improved neurological scores. The EM2-mediated protection was associated with a comparative decrease in BBB leakage, inflammatory infiltration, and higher expression levels of tight junction proteins, such as zonula occludens-1 and Occludin. I\/R-induced high expression of Rho-associated protein kinase 2 (ROCK2) was down-regulated after EM2 treatment. Moreover, EM2 reduced agonist doxazosin-induced EphA2 phosphorylation and cells rounding in PC3 cells, indicating EphA2-antagonizing activity of EM2. These finding provided evidences of the neuroprotection of EphA2 antagonist and a novel approach for ischemic stroke treatment. These results also suggested that a receptor agonist can be switched to an antagonist by substituting one or more relevant residues.<\/jats:p>","DOI":"10.1038\/s41598-017-02091-7","type":"journal-article","created":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T07:54:30Z","timestamp":1494316470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Design and evaluation of EphrinA1 mutants with cerebral protective effect"],"prefix":"10.1038","volume":"7","author":[{"given":"Yuanjun","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Shui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,15]]},"reference":[{"key":"2091_CR1","unstructured":"Thrift, A. G. et al. Global stroke statistics. Int J Stroke, doi:1747493016676285 (2016)."},{"key":"2091_CR2","unstructured":"Cai, W. et al. Dysfunction of the neurovascular unit in ischemic stroke and neurodegenerative diseases: An aging effect. Ageing Res Rev, doi:S1568-1637(16)30117-9 (2016)."},{"key":"2091_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3389\/fncel.2014.00231","volume":"8","author":"RA Posada-Duque","year":"2014","unstructured":"Posada-Duque, R. A., Barreto, G. E. & Cardona-Gomez, G. P. Protection after stroke: cellular effectors of neurovascular unit integrity. Front Cell Neurosci \n                           8, 231, doi:10.3389\/fncel.2014.00231 (2014).","journal-title":"Front Cell Neurosci"},{"key":"2091_CR4","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nm.3407","volume":"19","author":"B Obermeier","year":"2013","unstructured":"Obermeier, B., Daneman, R. & Ransohoff, R. M. Development, maintenance and disruption of the blood-brain barrier. Nat Med \n                           19, 1584\u20131596, doi:10.1038\/nm.3407 (2013).","journal-title":"Nat Med"},{"key":"2091_CR5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1051\/jbio\/2012020","volume":"206","author":"V Berezowski","year":"2012","unstructured":"Berezowski, V., Mysiorek, C., Kuntz, M., Petrault, O. & Cecchelli, R. [Dysfunction of the blood-brain barrier during ischaemia: a therapeutic concern]. Biol Aujourdhui \n                           206, 161\u2013176, doi:10.1051\/jbio\/2012020 (2012).","journal-title":"Biol Aujourdhui"},{"key":"2091_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.nbd.2008.08.005","volume":"32","author":"KE Sandoval","year":"2008","unstructured":"Sandoval, K. E. & Witt, K. A. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis \n                           32, 200\u2013219, doi:10.1016\/j.nbd.2008.08.005 (2008).","journal-title":"Neurobiol Dis"},{"key":"2091_CR7","doi-asserted-by":"crossref","unstructured":"Himanen, J. P. & Nikolov, D. B. Eph receptors and ephrins. Int J Biochem Cell Biol \n                           35, 130\u2013134, doi:S1357272502000961 (2003).","DOI":"10.1016\/S1357-2725(02)00096-1"},{"key":"2091_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrd4175","volume":"13","author":"AW Boyd","year":"2014","unstructured":"Boyd, A. W., Bartlett, P. F. & Lackmann, M. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov \n                           13, 39\u201362, doi:10.1038\/nrd4175 (2014).","journal-title":"Nat Rev Drug Discov"},{"key":"2091_CR9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.ajpath.2012.06.043","volume":"181","author":"MG Coulthard","year":"2012","unstructured":"Coulthard, M. G. et al. Eph\/Ephrin signaling in injury and inflammation. Am J Pathol \n                           181, 1493\u20131503, doi:10.1016\/j.ajpath.2012.06.043 (2012).","journal-title":"Am J Pathol"},{"key":"2091_CR10","doi-asserted-by":"crossref","unstructured":"Naruse-Nakajima, C., Asano, M. & Iwakura, Y. Involvement of EphA2 in the formation of the tail notochord via interaction with ephrinA1. Mech Dev \n                           102, 95\u2013105, doi:S0925477301002908 (2001).","DOI":"10.1016\/S0925-4773(01)00290-8"},{"key":"2091_CR11","doi-asserted-by":"publisher","first-page":"e53528","DOI":"10.1371\/journal.pone.0053528","volume":"8","author":"J Thundyil","year":"2013","unstructured":"Thundyil, J. et al. Evidence that the EphA2 receptor exacerbates ischemic brain injury. PLoS One \n                           8, e53528, doi:10.1371\/journal.pone.0053528 (2013).","journal-title":"PLoS One"},{"key":"2091_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.mvr.2011.06.005","volume":"82","author":"N Zhou","year":"2011","unstructured":"Zhou, N. et al. Inactivation of EphA2 promotes tight junction formation and impairs angiogenesis in brain endothelial cells. Microvasc Res \n                           82, 113\u2013121, doi:10.1016\/j.mvr.2011.06.005 (2011).","journal-title":"Microvasc Res"},{"key":"2091_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/embor.2009.91","volume":"10","author":"JP Himanen","year":"2009","unstructured":"Himanen, J. P. et al. Ligand recognition by A-class Eph receptors: crystal structures of the EphA2 ligand-binding domain and the EphA2\/ephrin-A1 complex. EMBO Rep \n                           10, 722\u2013728, doi:10.1038\/embor.2009.91 (2009).","journal-title":"EMBO Rep"},{"key":"2091_CR14","doi-asserted-by":"publisher","first-page":"46974","DOI":"10.1074\/jbc.M208495200","volume":"277","author":"M Koolpe","year":"2002","unstructured":"Koolpe, M., Dail, M. & Pasquale, E. B. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem \n                           277, 46974\u201346979, doi:10.1074\/jbc.M208495200 (2002).","journal-title":"J Biol Chem"},{"key":"2091_CR15","doi-asserted-by":"publisher","first-page":"14012","DOI":"10.1074\/jbc.M111.311670","volume":"287","author":"CM Lema Tome","year":"2012","unstructured":"Lema Tome, C. M. et al. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem \n                           287, 14012\u201314022, doi:10.1074\/jbc.M111.311670 (2012).","journal-title":"J Biol Chem"},{"key":"2091_CR16","doi-asserted-by":"crossref","unstructured":"Cao, G. et al. In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis. J Neurosci \n                           22, 5423\u20135431, doi:20026550 (2002).","DOI":"10.1523\/JNEUROSCI.22-13-05423.2002"},{"key":"2091_CR17","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.expneurol.2010.11.009","volume":"227","author":"B Cai","year":"2011","unstructured":"Cai, B. et al. TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. Exp Neurol \n                           227, 224\u2013231, doi:10.1016\/j.expneurol.2010.11.009 (2011).","journal-title":"Exp Neurol"},{"key":"2091_CR18","doi-asserted-by":"publisher","first-page":"e93334","DOI":"10.1371\/journal.pone.0093334","volume":"9","author":"Y Zhu","year":"2014","unstructured":"Zhu, Y., Bu, Q., Liu, X., Hu, W. & Wang, Y. Neuroprotective effect of TAT-14-3-3epsilon fusion protein against cerebral ischemia\/reperfusion injury in rats. PLoS One \n                           9, e93334, doi:10.1371\/journal.pone.0093334 (2014).","journal-title":"PLoS One"},{"key":"2091_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1242\/jcs.017145","volume":"121","author":"WB Fang","year":"2008","unstructured":"Fang, W. B. et al. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci \n                           121, 358\u2013368, doi:10.1242\/jcs.017145 (2008).","journal-title":"J Cell Sci"},{"key":"2091_CR20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/ncb796","volume":"4","author":"E Sahai","year":"2002","unstructured":"Sahai, E. & Marshall, C. J. ROCK and Dia have opposing effects on adherens junctions downstream of Rho. Nat Cell Biol \n                           4, 408\u2013415, doi:10.1038\/ncb796 (2002).","journal-title":"Nat Cell Biol"},{"key":"2091_CR21","doi-asserted-by":"crossref","unstructured":"Turner, N. A., O\u2019Regan, D. J., Ball, S. G. & Porter, K. E. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA\/ROCK pathway and reducing MMP-9 mRNA levels. FASEB J \n                           19, 804\u2013806, doi:04-2852fje (2005).","DOI":"10.1096\/fj.04-2852fje"},{"key":"2091_CR22","doi-asserted-by":"crossref","unstructured":"Iizuka, M. et al. Distinct distribution and localization of Rho-kinase in mouse epithelial, muscle and neural tissues. Cell Struct Funct \n                           37, 155\u2013175, doi:DN\/JST.JSTAGE\/csf\/12018 (2012).","DOI":"10.1247\/csf.12018"},{"key":"2091_CR23","doi-asserted-by":"crossref","unstructured":"Nakagawa, O. et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine\/threonine kinase in mice. FEBS Lett \n                           392, 189\u2013193, doi:0014-5793(96)00811-3 (1996).","DOI":"10.1016\/0014-5793(96)00811-3"},{"key":"2091_CR24","doi-asserted-by":"publisher","first-page":"e42120","DOI":"10.1371\/journal.pone.0042120","volume":"7","author":"A Petty","year":"2012","unstructured":"Petty, A. et al. A small molecule agonist of EphA2 receptor tyrosine kinase inhibits tumor cell migration in vitro and prostate cancer metastasis in vivo. PLoS One \n                           7, e42120, doi:10.1371\/journal.pone.0042120 (2012).","journal-title":"PLoS One"},{"key":"2091_CR25","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1111\/bph.12669","volume":"171","author":"I Hassan-Mohamed","year":"2014","unstructured":"Hassan-Mohamed, I. et al. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol \n                           171, 5195\u20135208, doi:10.1111\/bph.12669 (2014).","journal-title":"Br J Pharmacol"},{"key":"2091_CR26","doi-asserted-by":"publisher","first-page":"16017","DOI":"10.1074\/jbc.M709934200","volume":"283","author":"WB Fang","year":"2008","unstructured":"Fang, W. B., Brantley-Sieders, D. M., Hwang, Y., Ham, A. J. & Chen, J. Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase. J Biol Chem \n                           283, 16017\u201316026, doi:10.1074\/jbc.M709934200 (2008).","journal-title":"J Biol Chem"},{"key":"2091_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.brainres.2009.05.025","volume":"1280","author":"A Durukan","year":"2009","unstructured":"Durukan, A. et al. Post-ischemic blood-brain barrier leakage in rats: one-week follow-up by MRI. Brain Res \n                           1280, 158\u2013165, doi:10.1016\/j.brainres.2009.05.025 (2009).","journal-title":"Brain Res"},{"key":"2091_CR28","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.thromres.2008.07.010","volume":"123","author":"B Chan","year":"2009","unstructured":"Chan, B. & Sukhatme, V. P. Receptor tyrosine kinase EphA2 mediates thrombin-induced upregulation of ICAM-1 in endothelial cells in vitro. Thromb Res \n                           123, 745\u2013752, doi:10.1016\/j.thromres.2008.07.010 (2009).","journal-title":"Thromb Res"},{"key":"2091_CR29","doi-asserted-by":"publisher","first-page":"2 9 1","DOI":"10.1002\/cpps.20","volume":"86","author":"B Webb","year":"2016","unstructured":"Webb, B. & Sali, A. Comparative Protein Structure Modeling Using MODELLER. Curr Protoc Protein Sci \n                           86, 2 9 1\u20132 9 37, doi:10.1002\/cpps.20 (2016).","journal-title":"Curr Protoc Protein Sci"},{"key":"2091_CR30","first-page":"425","volume":"13","author":"RW Hooft","year":"1997","unstructured":"Hooft, R. W., Sander, C. & Vriend, G. Objectively judging the quality of a protein structure from a Ramachandran plot. Comput Appl Biosci \n                           13, 425\u2013430 (1997).","journal-title":"Comput Appl Biosci"},{"key":"2091_CR31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/356083a0","volume":"356","author":"R Luthy","year":"1992","unstructured":"Luthy, R., Bowie, J. U. & Eisenberg, D. Assessment of protein models with three-dimensional profiles. Nature \n                           356, 83\u201385, doi:10.1038\/356083a0 (1992).","journal-title":"Nature"},{"key":"2091_CR32","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/prot.10389","volume":"52","author":"R Chen","year":"2003","unstructured":"Chen, R., Li, L. & Weng, Z. ZDOCK: an initial-stage protein-docking algorithm. Proteins \n                           52, 80\u201387, doi:10.1002\/prot.10389 (2003).","journal-title":"Proteins"},{"key":"2091_CR33","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/prot.10460","volume":"53","author":"L Li","year":"2003","unstructured":"Li, L., Chen, R. & Weng, Z. RDOCK: refinement of rigid-body protein docking predictions. Proteins \n                           53, 693\u2013707, doi:10.1002\/prot.10460 (2003).","journal-title":"Proteins"},{"key":"2091_CR34","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0076-6879(09)63017-2","volume":"463","author":"RR Burgess","year":"2009","unstructured":"Burgess, R. R. Refolding solubilized inclusion body proteins. Methods Enzymol \n                           463, 259\u2013282, doi:10.1016\/S0076-6879 (2009). (09)63017-2.","journal-title":"Methods Enzymol"},{"key":"2091_CR35","doi-asserted-by":"publisher","unstructured":"Shui, M., Liu, X., Zhu, Y. & Wang, Y. Exogenous hydrogen sulfide attenuates cerebral ischemia-reperfusion injury by inhibiting autophagy in mice. Can J Physiol Pharmacol, 1\u20136, doi:10.1139\/cjpp-2016-0100 (2016).","DOI":"10.1139\/cjpp-2016-0100"},{"key":"2091_CR36","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/jnr.23420","volume":"92","author":"K Deguchi","year":"2014","unstructured":"Deguchi, K. et al. Pericyte protection by edaravone after tissue plasminogen activator treatment in rat cerebral ischemia. J Neurosci Res \n                           92, 1509\u20131519, doi:10.1002\/jnr.23420 (2014).","journal-title":"J Neurosci Res"},{"key":"2091_CR37","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.brainres.2011.12.016","volume":"1436","author":"K Deguchi","year":"2012","unstructured":"Deguchi, K. et al. Modifying neurorepair and neuroregenerative factors with tPA and edaravone after transient middle cerebral artery occlusion in rat brain. Brain Res \n                           1436, 168\u2013177, doi:10.1016\/j.brainres.2011.12.016 (2012).","journal-title":"Brain Res"},{"key":"2091_CR38","doi-asserted-by":"publisher","unstructured":"Rousselet, E., Kriz, J. & Seidah, N. G. Mouse model of intraluminal MCAO: cerebral infarct evaluation by cresyl violet staining. Journal of visualized experiments: JoVE, doi:10.3791\/4038 (2012).","DOI":"10.3791\/4038"},{"key":"2091_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.neulet.2012.11.052","volume":"534","author":"P Zhang","year":"2013","unstructured":"Zhang, P. et al. Honokiol inhibits the inflammatory reaction during cerebral ischemia reperfusion by suppressing NF-kappaB activation and cytokine production of glial cells. Neurosci Lett \n                           534, 123\u2013127, doi:10.1016\/j.neulet.2012.11.052 (2013).","journal-title":"Neurosci Lett"},{"key":"2091_CR40","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1161\/STROKEAHA.108.534503","volume":"40","author":"M Gelderblom","year":"2009","unstructured":"Gelderblom, M. et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke \n                           40, 1849\u20131857, doi:10.1161\/STROKEAHA.108.534503 (2009).","journal-title":"Stroke"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02091-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02091-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02091-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T04:17:27Z","timestamp":1671769047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-02091-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["2091"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-02091-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,15]]},"assertion":[{"value":"18 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1881"}}